30 Apr 2018 07:00
MaxCyte, Inc.
("MaxCyte" or the "Company")
Notice of AGM and 2017 Annual Report and Accounts
Gaithersburg, Maryland - 30 April 2018: MaxCyte (LSE: MXCT, MXCR), the global cell-based medicines and life sciences company, gives notice that copies of the 2017 Annual Report and Accounts and the Notice of Annual General Meeting have been sent to Stockholders. These documents are available on the "Investors" section of the Company's website at www.maxcyte.com.
Further copies of the Annual Report will be available from the Company Secretary, MaxCyte, Inc., 22 Firstfield Road, Suite 110, Gaithersburg, MD 20878, USA.
MaxCyte also announces that its Annual General Meeting of Stockholders is planned to be held on 31 October 2018. Formal notice and resolutions, along with the Annual Meeting Proxy Card, will be circulated on or about 10 September 2018 to Stockholders of record on or about that date.
###
For further information, please contact:
MaxCyte Inc. |
|
Doug Doerfler, Chief Executive Officer Ron Holtz, Chief Financial Officer | +1 301 944 1660 |
Nominated Adviser and Broker Panmure Gordon |
|
Freddy Crossley Ryan McCarthy
| +44 (0) 20 7886 2500
|
Financial PR Adviser Consilium Strategic Communications |
|
Mary-Jane Elliott Chris Welsh Suki Virji
| +44 (0)203 709 5700 maxcyte@consilium-comms.com |
About MaxCyte
MaxCyte is a global cell-based medicines and life sciences company applying its patented cell engineering technology to help patients with high unmet medical needs in a broad range of conditions. MaxCyte is developing novel CARMA™ therapies for its own pipeline. CARMA is MaxCyte's mRNA-based proprietary platform for autologous cell therapy. In addition, through its core business, the Company leverages its Flow Electroporation® Technology to enable its partners across the biopharmaceutical industry to advance the development of innovative medicines, particularly in cell therapy, including gene editing and immuno-oncology. The Company has placed its cutting-edge flow electroporation instruments worldwide, including with nine of the top ten global biopharmaceutical companies, and has more than 50 partnered programme licences in cell therapy including more than 20 licensed for clinical use. With its robust delivery technology, MaxCyte helps its partners to unlock the full potential of their products.
For more information, visit www.maxcyte.com.
MaxCyte (MXCT)